export default {
  name: "Johnson & Johnson",
  industry: "Pharmaceuticals and MedTech",
  score: 80,
  revenueRisk: "$1.6B (FY24 acquired IPR&D charges impacting customer acquisition and retention)",

  leaks: [
    {
      issue: "Ongoing talc-related litigation damaging brand trust",
      impact: "Risk of customer churn among healthcare providers and patients, increasing retention costs",
      solution: "Enhance transparency and accelerate settlement resolutions",
      source: {
        label: "Johnson & Johnson SWOT Analysis 2025",
        url: "https://businessmodelanalyst.com/johnson-johnson-swot-analysis/"
      }
    },
    {
      issue: "Slow R&D cycles delaying new product launches",
      impact: "Increased customer acquisition costs and retention risks from competitive lag",
      solution: "Streamline R&D processes to accelerate market entry",
      source: {
        label: "Johnson & Johnson SWOT Analysis 2025",
        url: "https://businessmodelanalyst.com/johnson-johnson-swot-analysis/"
      }
    }
  ],

  strengths: [
    {
      item: "MedTech segment achieved 6.2% operational sales growth in 2024",
      source: {
        label: "Johnson & Johnson 2024 Full Year Results",
        url: "https://www.investor.jnj.com"
      }
    },
    {
      item: "Pipeline progress with TREMFYA and RYBREVANT approvals enhancing customer trust",
      source: {
        label: "Johnson & Johnson Q3 2024 Results",
        url: "https://www.investor.jnj.com"
      }
    }
  ]
          }
